Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 1 | 0 | 1 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 1 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $97.43, along with a high estimate of $125.00 and a low estimate of $65.00. This upward trend is apparent, with the current average reflecting a 73.98% increase from the previous average price target of $56.00.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent...
Login or create a forever free account to read this news
Sign up/Log in